Loading clinical trials...

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis

NCT04071769•Duke University

Summary

The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments. Participants will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyper-polarized 129 Xenon. The subjects will have this initial study prior to initiation of IPF therapies. Then the participants will have repeat studies at 3, 6 and 12 months following the initiation of therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Outpatients of either gender, age \> 18.
•Willing and able to give informed consent and adhere to visit/protocol schedules.
•(Consent must be given before any study procedures are performed)
•Clinical diagnosis of IPF by confirmed by multidisciplinary diagnosis and naïve to treatment with an approved IPF therapy (either nintedanib or pirfenidone)

Exclusion Criteria

•Subject is less than 18 years old
•Subjects who have been previously on either pirfenidone or nintedanib
•MRI is contraindicated based on responses to MRI screening questionnaire
•Subject is pregnant or lactating
•Resting oxygen saturation on room air \<90% on supplemental oxygen
•Respiratory illness of a bacterial or viral etiology within 30 days of MRI
•Subject with ventricular cardiac arrhythmia in the past 30 days.
•Subject has history of cardiac arrest within the last year
•Subject does not fit into 129 Xenon vest coil used for MRI
•Subject deemed unlikely to be able to comply with instructions during imaging
+2 more criteria

Locations (1)

Duke University Medical Center

Durham, North Carolina, United States

Key Dates

Start Date

August 3, 2020

Primary Completion Date

October 17, 2024

Completion Date

September 30, 2029

Last Updated

January 2, 2026

Enrollment

ACTUAL participants

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment

DRUG

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis

View study

RECRUITINGPHASE3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695

Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

Inclusion Criteria

Exclusion Criteria

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

Validation of the C-mo System - Cough Monitoring